Cargando…

Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke

OBJECTIVE: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS). METHODS: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Insti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Mei, Lei, Hongyan, Cui, Yansen, Yang, Daiqun, Wang, Liquang, Wang, Ziran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017082/
https://www.ncbi.nlm.nih.gov/pubmed/27648019
http://dx.doi.org/10.12669/pjms.324.9518
_version_ 1782452678871220224
author Zheng, Mei
Lei, Hongyan
Cui, Yansen
Yang, Daiqun
Wang, Liquang
Wang, Ziran
author_facet Zheng, Mei
Lei, Hongyan
Cui, Yansen
Yang, Daiqun
Wang, Liquang
Wang, Ziran
author_sort Zheng, Mei
collection PubMed
description OBJECTIVE: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS). METHODS: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment. RESULTS: The NIHSS scores of the three groups were significantly reduced after the treatment (P<0.05), among which the NIHSS score of group A was the lowest (P<0.05); and the difference between group B and C was not significant (P>0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P>0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant. CONCLUSIONS: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).
format Online
Article
Text
id pubmed-5017082
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-50170822016-09-19 Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke Zheng, Mei Lei, Hongyan Cui, Yansen Yang, Daiqun Wang, Liquang Wang, Ziran Pak J Med Sci Original Article OBJECTIVE: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS). METHODS: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment. RESULTS: The NIHSS scores of the three groups were significantly reduced after the treatment (P<0.05), among which the NIHSS score of group A was the lowest (P<0.05); and the difference between group B and C was not significant (P>0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P>0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant. CONCLUSIONS: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS). Professional Medical Publications 2016 /pmc/articles/PMC5017082/ /pubmed/27648019 http://dx.doi.org/10.12669/pjms.324.9518 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zheng, Mei
Lei, Hongyan
Cui, Yansen
Yang, Daiqun
Wang, Liquang
Wang, Ziran
Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
title Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
title_full Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
title_fullStr Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
title_full_unstemmed Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
title_short Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
title_sort clinical efficacy and safety of hypernormal shortened door to needle time (dnt) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017082/
https://www.ncbi.nlm.nih.gov/pubmed/27648019
http://dx.doi.org/10.12669/pjms.324.9518
work_keys_str_mv AT zhengmei clinicalefficacyandsafetyofhypernormalshorteneddoortoneedletimedntplusindividualizedlowdosealteplasetherapyintreatingacuteischemicstroke
AT leihongyan clinicalefficacyandsafetyofhypernormalshorteneddoortoneedletimedntplusindividualizedlowdosealteplasetherapyintreatingacuteischemicstroke
AT cuiyansen clinicalefficacyandsafetyofhypernormalshorteneddoortoneedletimedntplusindividualizedlowdosealteplasetherapyintreatingacuteischemicstroke
AT yangdaiqun clinicalefficacyandsafetyofhypernormalshorteneddoortoneedletimedntplusindividualizedlowdosealteplasetherapyintreatingacuteischemicstroke
AT wangliquang clinicalefficacyandsafetyofhypernormalshorteneddoortoneedletimedntplusindividualizedlowdosealteplasetherapyintreatingacuteischemicstroke
AT wangziran clinicalefficacyandsafetyofhypernormalshorteneddoortoneedletimedntplusindividualizedlowdosealteplasetherapyintreatingacuteischemicstroke